

《食道癌抗癌藥物治療指引》

115 年版與上一版差異

114 年版 修訂日 114/01/21	115 年版 修訂日 114/11/25
Perioperative Chemotherapy	Perioperative Chemotherapy ■ 修改 FOLFOX：Preferred → Other ■ 新增 FLOT + Durvalumab
Systemic therapy for metastatic or locally advanced cancer	Systemic therapy for metastatic or locally advanced cancer ■ 新增 Zolbetuximab-clzb + Chemo • FOLFOX • CapeOx ■ 新增 Tisleizumab-isgr + Chemo • Cisplatin + 5FU • Oxaliplatin + 5FU • Cisplatin + Capecitabine • Oxaliplatin + Capecitabine

《 食道癌抗癌藥物治療指引 》

Perioperative Chemotherapy

(Only for adenocarcinoma of the thoracic esophagus or EGJ)

Preferred Regimens

ECF modications

藥品名	劑量 mg/m ²	輸注時間	給藥日	頻率	週期	參考文獻
Epirubicin	50	≥ 30 mins	d1	Q3W	6*	9
Cisplatin	60	≥ 2 hrs	d1	Q3W	6*	
Capecitabine	625 PO BID		d1-21	Q3W	6*	

*3(pre-op) + 3(post-op)

藥品名	劑量 mg/m ²	輸注時間	給藥日	頻率	週期	參考文獻
Epirubicin	50	≥ 30 mins	d1	Q3W	6*	9
Oxaliplatin	130	2 hrs	d1	Q3W	6*	
Capecitabine	625 PO BID		d1-21	Q3W	6*	

*3(pre-op) + 3(post-op)

Oxaliplatin + Fluoropyrimidine

藥品名	劑量 mg/m ²	輸注時間	給藥日	頻率	週期	參考文獻
Oxaliplatin	85	2 hrs	d1	Q2W	6*	19
Leucovorin	200	≥ 90 mins	d1	Q2W	6*	
5-FU	2600	22-24 hrs	d1	Q2W	6*	

*3 (pre-op) + 3 (post-op)

藥品名	劑量 mg/m ²	輸注時間	給藥日	頻率	週期	參考文獻
Oxaliplatin	130	2 hrs	d1	Q3W	6 [#]	23
Capecitabine	1000 PO BID		d1-14	Q3W	6 [#]	

#3 (pre-op) + 3 (post-op)

FLOT

藥品名	劑量 mg/m ²	輸注時間	給藥日	頻率	週期	參考文獻
Docetaxel	50	1 hr	d1	Q2W	8 [#]	8
Oxaliplatin	85	2 hrs	d1	Q2W	8 [#]	
Leucovorin	200	≥ 90 mins	d1	Q2W	8 [#]	
5-FU	2600	22-24 hrs	d1	Q2W	8 [#]	

#4 (pre-op) + 4 (post-op)

FLOT + Durvalumab

藥品名	劑量 mg/m ²	輸注時間	給藥日	頻率	週期	參考文獻
Durvalumab	1500 mg	1 hr	d1	Q4W	2 pre + 2 post OP	8
Oxaliplatin	85	2 hrs	d1, 15	Q4W	2 pre + 2 post OP	
Docetaxel	50	1 hr	d1, 15	Q4W	2 pre + 2 post OP	
Leucovorin	200	≥ 90 mins	d1, 15	Q4W	2 pre + 2 post OP	
5-FU	2600	22-24 hrs	d1, 15	Q4W	2 pre + 2 post OP	
Followed by						
Durvalumab	1500 mg	1 hr	d1	Q4W	10	

Other Regimens

Oxaliplatin + Fluoropyrimidine

藥品名	劑量 mg/m ²	輸注時間	給藥日	頻率	週期	參考文獻
Oxaliplatin	85	2 hrs	d1	Q2W	6 [#]	22
Leucovorin	400	≥ 90 mins	d1	Q2W	6 [#]	
5-FU	400	5 mins	d1	Q2W	6 [#]	
5-FU	1200	22-24 hrs	d1-2	Q2W	6 [#]	

[#]3 (pre-op) + 3 (post-op)

Cisplatin + Fluorouracil

藥品名	劑量 mg/m ²	輸注時間	給藥日	頻率	週期	參考文獻
Cisplatin	100	≥ 4 hrs	d1	Q4W	6 [#]	9
5-Fu	800	22-24 hrs	d1-5	Q4W	6 [#]	

[#]2-3 (pre-op) + 3-4 (post-op)

Preoperative Chemotherapy

(Only for adenocarcinoma of the thoracic esophagus or EGJ)

Cisplatin + Fluorouracil

藥品名	劑量 mg/m ²	輸注時間	給藥日	頻率	週期	參考文獻
Cisplatin	80	≥ 4 hrs	d1	Q3W	2 [#]	10
5-Fu	1000	22-24 hrs	d1-4	Q3W	2 [#]	

[#]2(pre-op)

Postoperative Chemotherapy

Preferred Regimens

Nivolumab only after preoperative chemoradiation with R0 resection and residual disease

藥品名	劑量 mg/m ²	輸注時間	給藥日	頻率	週期	參考文獻
Nivolumab	240 mg	≥ 30 mins	d1	Q2W	8	49
Followed by Nivolumab	480 mg	≥ 30 mins	d1	Q4W	For max 1 year	

Other Recommended Regimens

Oxaliplatin + Capecitabine

藥品名	劑量 mg/m ²	輸注時間	給藥日	頻率	週期	參考文獻
Oxaliplatin	130	2 hrs	d1	Q3W		16
Capecitabine	1000 PO BID		d1-14	Q3W		

Oxaliplatin + Fluorouracil

藥品名	劑量 mg/m ²	輸注時間	給藥日	頻率	週期	參考文獻
Oxaliplatin	85	2 hrs	d1	Q2W		22
Leucovorin	400	≥ 90 mins	d1	Q2W		
5-FU	400	5 mins	d1	Q2W		
5-FU	1200	22-24 hrs	d1-2	Q2W		

藥品名	劑量 mg/m ²	輸注時間	給藥日	頻率	週期	參考文獻
Oxaliplatin	85	2 hrs	d1	Q2W		19
Leucovorin	200	≥ 90 mins	d1	Q2W		
5-FU	2600	22-24 hrs	d1	Q2W		

Preoperative Chemoradiation Therapy of Esophageal Cancer

Preferred Regimens

Paclitaxel + Carboplatin

藥品名	劑量 mg/m ²	輸注時間	給藥日	頻率	週期	參考文獻
Paclitaxel	50	≥ 1 hr	d1	QW	5	1
Carboplatin	AUC 2	≥ 30 mins	d1	QW	5	

Oxaliplatin + Fluoropyrimidine

藥品名	劑量 mg/m ²	輸注時間	給藥日	頻率	週期	參考文獻
Oxaliplatin	85	2 hrs	d1	Q2W	3(RT) + 3	2
Leucovorin	400	≥ 90 mins	d1	Q2W	3(RT) + 3	
5-FU	400	5 mins	d1	Q2W	3(RT) + 3	
5-FU	800	22-24 hrs	d1-2	Q2W	3(RT) + 3	

藥品名	劑量 mg/m ²	輸注時間	給藥日	頻率	週期	參考文獻
Oxaliplatin	85	2 hrs	d1, 15, 29		For 3 doses	42
Capecitabine	625 PO BID		d1-5	QW	5	

Other Regimens

Cisplatin + Fluoropyrimidine

藥品名	劑量 mg/m ²	輸注時間	給藥日	頻率	週期	參考文獻
Cisplatin	75	≥ 4 hrs	d1	Q4W	2(RT) + 2	2
5-FU	1000	22-24 hrs	d1-4	Q4W	2(RT) + 2	

藥品名	劑量 mg/m ²	輸注時間	給藥日	頻率	週期	參考文獻
Cisplatin	15	≥ 1 hr	d1-5	Q3W	2	5
5-FU	800	22-24 hrs	d1-5	Q3W	2	

藥品名	劑量 mg/m ²	輸注時間	給藥日	頻率	週期	參考文獻
Cisplatin	30	≥ 2 hrs	d1	QW	5	43
Capecitabine	800 PO BID		d1-5	QW	5	

藥品名	劑量 mg/m ²	輸注時間	給藥日	頻率	週期	參考文獻
Cisplatin	100	≥ 4 hrs	d1, 29	Q35D	1	4
5-Fu	1000	22-24 hrs	d1-4, 29-32	Q35D	1	

Irinotecan + Cisplatin

藥品名	劑量 mg/m ²	輸注時間	給藥日	頻率	週期	參考文獻
Irinotecan	65	≥ 90 mins	d1, 8, 22, 29		1	6
Cisplatin	30	≥ 2 hrs	d1, 8, 22, 29		1	

Paclitaxel + Fluorouracil

藥品名	劑量 mg/m ²	輸注時間	給藥日	頻率	週期	參考文獻
Paclitaxel	45	≥ 1 hr	d1	QW	5	7
5-FU	300	22-24 hrs	d1-5	QW	5	

Definitive Chemoradiation (Non-Surgical)

Preferred Regimens

Oxaliplatin + Fluoropyrimidine

藥品名	劑量 mg/m ²	輸注時間	給藥日	頻率	週期	參考文獻
Oxaliplatin	85	2 hrs	d1	Q2W	6 [#]	5
Leucovorin	400	≥ 90 mins	d1	Q2W	6 [#]	
5-FU	400	5 mins	d1	Q2W	6 [#]	
5-FU	800	22-24 hrs	d1-2	Q2W	6 [#]	

[#]3 (RT) + 3 (post-RT)

藥品名	劑量 mg/m ²	輸注時間	給藥日	頻率	週期	參考文獻
Oxaliplatin	85	2 hrs	d1, 15, 29		For 3 doses	42
Capecitabine	625 PO BID		d1-5	QW	5	

藥品名	劑量 mg/m ²	輸注時間	給藥日	頻率	週期	參考文獻
Oxaliplatin	85	2 hrs	d1, 15, 29			3
5-FU	180		d1-33			

Paclitaxel + Carboplatin

藥品名	劑量 mg/m ²	輸注時間	給藥日	頻率	週期	參考文獻
Paclitaxel	50	≥ 1 hr	d1	QW	5	1
Carboplatin	AUC 2	≥ 30 mins	d1	QW	5	

Cisplatin + Fluoropyrimidine

藥品名	劑量 mg/m ²	輸注時間	給藥日	頻率	週期	參考文獻
Cisplatin	75	≥ 4 hrs	d1	Q4W	2~4 [#]	11
5-FU	1000	22-24 hrs	d1-4	Q4W	2~4 [#]	

[#]2 (RT) + 2

藥品名	劑量 mg/m ²	輸注時間	給藥日	頻率	週期	參考文獻
Cisplatin	30	≥ 2 hrs	d1	QW	5	41
Capecitabine	800 PO BID		d1-5	QW	5	

Other Regimens

Taxane + Cisplatin

藥品名	劑量 mg/m ²	輸注時間	給藥日	頻率	週期	參考文獻
Paclitaxel	60	≥ 1 hr	d1, 8, 15, 22		1	12
Cisplatin	75	≥ 4 hrs	d1		1	

藥品名	劑量 mg/m ²	輸注時間	給藥日	頻率	週期	參考文獻
Docetaxel	60	1 hr	d1, 22		1	13
Cisplatin	80	≥ 4 hrs	d1, 22		1	

藥品名	劑量 mg/m ²	輸注時間	給藥日	頻率	週期	參考文獻
Docetaxel	30	1 hr	d1	QW	5	14
Cisplatin	30	≥ 2 hrs	d1	QW	5	

Irinotecan + Cisplatin

藥品名	劑量 mg/m ²	輸注時間	給藥日	頻率	週期	參考文獻
Irinotecan	65	≥ 90 mins	d1, 8, 22, 29		1	6
Cisplatin	30	≥ 2 hrs	d1, 8, 22, 29		1	

Paclitaxel + Fluoropyrimidine

藥品名	劑量 mg/m ²	輸注時間	給藥日	頻率	週期	參考文獻
Paclitaxel	45-50	≥ 1 hr	d1	QW	5	7
5-FU	300	22-24 hrs	d1-5	QW	5	

Postoperative Chemoradiation (Including EGJ)

5-FU (bolus) + Leucovorin

藥品名	劑量 mg/m ²	輸注時間	給藥日	頻率	週期	參考文獻
Lecucovorin	20	≥ 5 mins	d1-5	Q4W	1 st , 3 rd , 4 th #	15, 44
5-FU	425	≥ 5 mins	d1-5	Q4W	1 st , 3 rd , 4 th #	
Lecucovorin	20	≥ 5 mins	d1-4, 31-33	Q5W	2 nd (with RT)	
5-FU	400	≥ 5 mins	d1-4, 31-33	Q5W	2 nd (with RT)	

#Cycle 1st (pre-RT), and cycle 3rd, 4th (post-RT)

5-FU + Leucovorin modifications

1 cycle before + 2 cycle after chemoradiation

藥品名	劑量 mg/m ²	給藥日	頻率	週期	參考文獻
Capecitabine	1000 PO BID	d1-14	Q4W	1 + 2	45

2 cycle before + 4 cycle after chemoradiation

藥品名	劑量 mg/m ²	輸注時間	給藥日	頻率	週期	參考文獻
Leucovorin	400	≥ 90 mins	d1	Q2W	2 + 4	58
5-FU	400	5 mins	d1	Q2W	2 + 4	
5-FU	1200	22-24 hrs	d1-2	Q2W	2 + 4	

With radiation

藥品名	劑量 mg/m ²	輸注時間	給藥日	頻率	週期	參考文獻
5-FU	225	22-24 hrs	d1-5 or 1-7	QW	5 with RT	47

藥品名	劑量 mg/m ²	給藥日	頻率	週期	參考文獻
Capecitabine	825 PO BID	d1-5 or 1-7	QW	5 with RT	46

Neoadjuvant or Perioperative Immunotherapy

Nivolumab and Ipilimumab followed by Nivolumab (MSI-H/dMMR)

藥品名	劑量 mg/m ²	輸注時間	給藥日	頻率	週期	參考文獻
Nivolumab	240 mg	≥ 30 mins	d1	Q2W	Pre-OP X 6	54
Ipilimumab	1 mg/kg	≥ 30 mins	d1	Q6W	Pre-OP X 2	
Followed by surgery						
Nivolumab	480 mg	≥ 30 mins	d1	Q4W	Pre-OP X 9	

Pembrolizumab (MSI-H/dMMR)

藥品名	劑量 mg/m ²	輸注時間	給藥日	頻率	週期	參考文獻
Pembrolizumab	200 mg	≥ 30 mins	d1	Q3W	Pre-OP X 2	55, 56
Followed by surgery						
Pembrolizumab	200 mg	≥ 30 mins	d1	Q3W	Pre-OP X 5	

Tremelimumab + Durvalumab (MSI-H/dMMR) (for neoadjuvant therapy only)

藥品名	劑量 mg/m ²	輸注時間	給藥日	頻率	週期	參考文獻
Tremelimumab	300 mg	≥ 1 hr	d1	Q12W	Pre-OP X 1	57
Durvalumab	1500 mg	1 hr	d1	Q4W	Pre-OP X 3	

Systemic Therapy for Metastatic or Locally Advanced Cancer (where local therapy is not indicated)

First-line Therapy

Trastuzumab (with chemotherapy)

藥品名	劑量 mg/m ²	輸注時間	給藥日	頻率	週期	參考文獻
Trastuzumab	8 → 6 mg/kg	≥ 1 hr	d1	Q3W		17, 53

Trastuzumab (with chemotherapy)

藥品名	劑量 mg/m ²	輸注時間	給藥日	頻率	週期	參考文獻
Trastuzumab	6 → 4 mg/kg	≥ 1 hr	d1	Q2W		17

Tislelizumab-isgr (with Fluorouracil and Cisplatin or Oxaliplatin)

藥品名	劑量 mg/m ²	輸注時間	給藥日	頻率	週期	參考文獻
Tislelizumab-isgr	200 mg	60 → 30 mins	d1	Q3W		61

Preferred Regimens

± Nivolumab + Oxaliplatin + Capecitabine

藥品名	劑量 mg/m ²	輸注時間	給藥日	頻率	週期	參考文獻
± Nivolumab	360 mg	≥ 30 mins	d1	Q3W		50
Oxaliplatin	130	2 hrs	d1	Q3W		23
Capecitabine	850~1000* PO BID		d1-14	Q3W		

For adenocarcinoma (PD-L1 CPS: 1-4, category 2B; ≥ 5, category 1) or Squamous cell carcinoma.

*2023 NCCN & 團隊共識

± Nivolumab + Oxaliplatin + 5Fu

藥品名	劑量 mg/m ²	輸注時間	給藥日	頻率	週期	參考文獻
± Nivolumab	240 mg	≥ 30 mins	d1	Q2W		50
Oxaliplatin	85	2 hrs	d1	Q2W		22
Leucovorin	400	≥ 90 mins	d1	Q2W		
5-FU	400	5 mins	d1	Q2W		
5-FU	1200	22-24 hrs	d1-2	Q2W		

For adenocarcinoma (PD-L1 CPS: 1-4, category 2B; ≥ 5, category 1) or Squamous cell carcinoma.

Nivolumab + 5FU + Cisplatin

藥品名	劑量 mg/m ²	輸注時間	給藥日	頻率	週期	參考文獻
Nivolumab	360 mg	≥ 30 mins	d1	Q3W	Max 2 years	50
Cisplatin	80	≥ 4 hrs	d1	Q3W	Max 2 years	54
Capecitabine	850~1000* PO BID		d1-14	Q3W	Max 2 years	

*2023 NCCN & 團隊共識

Pembrolizumab + Oxaliplatin + Capecitabine

藥品名	劑量 mg/m ²	輸注時間	給藥日	頻率	週期	參考文獻
Pembrolizumab	200 mg	≥ 30 mins	d1	Q3W	Up to 2 years	51
Oxaliplatin	130	2 hrs	d1	Q3W	6	
Capecitabine	850~1000* PO BID		d1-14	Q3W	6	

*2023 NCCN & 團隊共識

Pembrolizumab + Oxaliplatin + 5Fu

藥品名	劑量 mg/m ²	輸注時間	給藥日	頻率	週期	參考文獻
Pembrolizumab	200 mg	≥ 30 mins	d1	Q2W	Up to 2 years	51
Oxaliplatin	85	2 hrs	d1	Q2W	9	
Leucovorin	400	≥ 90 mins	d1	Q2W	9	
5-FU	400	5 mins	d1	Q2W	9	
5-FU	1200	22-24 hrs	d1-2	Q2W	9	

Pembrolizumab + Cisplatin + 5Fu

藥品名	劑量 mg/m ²	輸注時間	給藥日	頻率	週期	參考文獻
Pembrolizumab	200 mg	≥ 30 mins	d1	Q3W	Up to 2 years	51
Cisplatin	80	≥ 4 hrs	d1	Q3W	6	
5-Fu	800	22-24 hrs	d1-5	Q3W	6	

Pembrolizumab + Cisplatin + Capecitabine

藥品名	劑量 mg/m ²	輸注時間	給藥日	頻率	週期	參考文獻
Pembrolizumab	200 mg	≥ 30 mins	d1	Q3W	Up to 2 years	51
Cisplatin	80	≥ 4 hrs	d1	Q3W	6	
Capecitabine	850~1000* PO BID		d1-14	Q3W	6	

*2023 NCCN & 團隊共識

Zolbetuximab-clzb for HER 2 negative, CLDN 18.2-positive, adenocarcinoma

藥品名	劑量 mg/m ²	輸注時間	給藥日	頻率	週期	參考文獻
Zolbetuximab-clzb	800 → 400	30-60 mins	d1	Q2W		59
Oxaliplatin	85	2 hrs	d1	Q2W	Up to 12 cycles	
Leucovorin	400	≥ 90 mins	d1	Q2W	Up to 12 cycles	
5-FU	400	5 mins	d1	Q2W	Up to 12 cycles	
5-FU	1200	22-24 hrs	d1-2	Q2W	Up to 12 cycles	

藥品名	劑量 mg/m ²	輸注時間	給藥日	頻率	週期	參考文獻
Zolbetuximab-clzb	800 → 600	30-60 mins	d1	Q3W		60
Oxaliplatin	130	2 hrs	d1	Q3W	Up to 8 cycles	
Capecitabine	850~1000 PO BID		d1-14	Q3W	Up to 8 cycles	

Fluoropyrimidine + Cisplatin

藥品名	劑量 mg/m ²	輸注時間	給藥日	頻率	週期	參考文獻
Cisplatin	100	≥ 4 hrs	d1	Q4W		18
5-FU	1000	22-24 hrs	d1-4	Q4W		

藥品名	劑量 mg/m ²	輸注時間	給藥日	頻率	週期	參考文獻
Cisplatin	50	≥ 2 hrs	d1	Q2W		19, 20
Leucovorin	200	≥ 90 mins	d1	Q2W		
5-FU	2000	22-24 hrs	d1	Q2W		

藥品名	劑量 mg/m ²	輸注時間	給藥日	頻率	週期	參考文獻
Cisplatin	80	≥ 4 hrs	d1	Q3W		21
Capecitabine	850~1000* PO BID		d1-14	Q3W		

*2023 NCCN & 團隊共識

藥品名	劑量 mg/m ²	輸注時間	給藥日	頻率	週期	參考文獻
Nivolumab	3 mg/kg	≥ 30 mins	d1	Q3W	Max 2 years	53
Ipilimumab	1 mg/kg	≥ 30 mins	d1	Q6W		

Fluoropyrimidine + Oxaliplatin

藥品名	劑量 mg/m ²	輸注時間	給藥日	頻率	週期	參考文獻
Oxaliplatin	85	2 hrs	d1	Q2W		19
Leucovorin	200	≥ 90 mins	d1	Q2W		
5-FU	2600	22-24 hrs	d1	Q2W		

藥品名	劑量 mg/m ²	輸注時間	給藥日	頻率	週期	參考文獻
Oxaliplatin	85	2 hrs	d1	Q3W		47
Capecitabine	625 PO BID		d1-14	Q3W		

MSI-H/dMMR tumors (independent of PD-L1 status)

藥品名	劑量 mg/m ²	輸注時間	給藥日	頻率	週期	參考文獻
Pembrolizumab	200 mg	≥ 30 mins	d1	Q3W		55

藥品名	劑量 mg/m ²	輸注時間	給藥日	頻率	週期	參考文獻
Pembrolizumab	400 mg	≥ 30 mins	d1	Q6W		56

藥品名	劑量 mg/m ²	輸注時間	給藥日	頻率	週期	參考文獻
Nivolumab	1 mg/kg	≥ 30 mins	d1	Q3W	4	57
Ipilimumab	3 mg/kg	≥ 30 mins	d1	Q3W	4	
Followed by						
Nivolumab	240 mg	≥ 30 mins	d1	Q2W	Max 2 years	

藥品名	劑量 mg/m ²	輸注時間	給藥日	頻率	週期	參考文獻
Nivolumab	240 mg	≥ 30 mins	d1	Q3W	4	57
Ipilimumab	1 mg/kg	≥ 30 mins	d1	Q3W	4	
Followed by						
Nivolumab	240 mg (480 mg)	≥ 30 mins	d1	Q2W (Q4W)	Max 2 years	

Tislelizumab-isgr combination with Fluoropyrimidine and Cisplatin or Oxaliplatin

藥品名	劑量 mg/m ²	輸注時間	給藥日	頻率	週期	參考文獻
Tislelizumab-isgr	200 mg	60 → 30 mins	d1	Q3W		61
Cisplatin	60-80	≥ 4 hrs	d1	Q3W		
5-FU	750-800	22-24 hrs	d1-5	Q3W		

藥品名	劑量 mg/m ²	輸注時間	給藥日	頻率	週期	參考文獻
Tislelizumab-isgr	200 mg	60 → 30 mins	d1	Q3W		61
Oxaliplatin	130	2 hrs	d1	Q3W		
5-FU	750-800	22-24 hrs	d1-5	Q3W		

藥品名	劑量 mg/m ²	輸注時間	給藥日	頻率	週期	參考文獻
Tislelizumab-isgr	200 mg	60 → 30 mins	d1	Q3W		61
Cisplatin	60-80	≥ 4 hrs	d1	Q3W		
Capecitabine	1000 PO BID		d1-14	Q3W		

藥品名	劑量 mg/m ²	輸注時間	給藥日	頻率	週期	參考文獻
Tislelizumab-isgr	200 mg	60 → 30 mins	d1	Q3W		61
Oxaliplatin	130	2 hrs	d1	Q3W		
Capecitabine	1000 PO BID		d1-14	Q3W		

Other Regimens

Paclitaxel + Cisplatin/Carboplatin

藥品名	劑量 mg/m ²	輸注時間	給藥日	頻率	週期	參考文獻
Paclitaxel	200	≥ 3 hrs	d1	Q3W		24
Cisplatin	75	≥ 4 hrs	d2	Q3W		

藥品名	劑量 mg/m ²	輸注時間	給藥日	頻率	週期	參考文獻
Paclitaxel	90	≥ 1 hrs	d1	Q2W		25
Cisplatin	50	≥ 2 hrs	d1	Q2W		

藥品名	劑量 mg/m ²	輸注時間	給藥日	頻率	週期	參考文獻
Paclitaxel	200	≥ 3 hrs	d1	Q3W		26
Carboplatin	AUC 5	1 hr	d1	Q3W		

Docetaxel + Cisplatin

藥品名	劑量 mg/m ² ★	輸注時間	給藥日	頻率	週期	參考文獻
Docetaxel	75-85	1 hr	d1	Q3W		27, 28
Cisplatin	70-75	≥ 4 hrs	d1	Q3W		

Fluoropyrimidine

藥品名	劑量 mg/m ²	輸注時間	給藥日	頻率	週期	參考文獻
Leucovorin	400	≥ 90 mins	d1	Q2W		20
5-FU	400	5 mins	d1	Q2W		
5-FU	1200	22-24 hrs	d1-2	Q2W		

藥品名	劑量 mg/m ²	輸注時間	給藥日	頻率	週期	參考文獻
5-FU	800	22-24 hrs	d1-5	Q4W		29

藥品名	劑量 mg/m ²	給藥日	頻率	週期	參考文獻
Capecitabine	1250 PO BID	d1-14	Q3W		30

Taxane

藥品名	劑量 mg/m ²	輸注時間	給藥日	頻率	週期	參考文獻
Docetaxel	100	1 hr	d1	Q3W		31, 32

藥品名	劑量 mg/m ²	輸注時間	給藥日	頻率	週期	參考文獻
Paclitaxel	250	≥ 3 hrs	d1	Q3W		33

藥品名	劑量 mg/m ²	輸注時間	給藥日	頻率	週期	參考文獻
Paclitaxel	80	≥ 1 hr	d1	QW		34

Irinotecan + 5-FU (only for adenocarcinoma)

藥品名	劑量 mg/m ²	輸注時間	給藥日	頻率	週期	參考文獻
Irinotecan	180	≥ 90 mins	d1	Q2W		35
Leucovorin	400	≥ 90 mins	d1	Q2W		
5-FU	400	5 mins	d1	Q2W		
5-FU	1200	22-24 hrs	d1-2	Q2W		

藥品名	劑量 mg/m ²	輸注時間	給藥日	頻率	週期	參考文獻
Irinotecan	80	≥ 90 mins	d1	QW	6 + 2(off) [#]	48
Leucovorin	500	≥ 90 mins	d1	QW	6 + 2(off) [#]	
5-FU	2000	22-24 hrs	d1	QW	6 + 2(off) [#]	

[#]6 weeks treatment, followed by 2 weeks off

ECF

藥品名	劑量 mg/m ²	輸注時間	給藥日	頻率	週期	參考文獻
Epirubicin	50	≥ 30 mins	d1	Q3W		38
Cisplatin	60	≥ 3 hrs	d1	Q3W		
5-Fu	200	22-24 hrs	d1-21	Q3W		

ECF modifications

藥品名	劑量 mg/m ²	輸注時間	給藥日	頻率	週期	參考文獻
Epirubicin	50	≥ 30 mins	d1	Q3W		39, 40
Oxaliplatin	130	2 hrs	d1	Q3W		
5-Fu	200	22-24 hrs	d1-21	Q3W		

藥品名	劑量 mg/m ²	輸注時間	給藥日	頻率	週期	參考文獻
Epirubicin	50	≥ 30 mins	d1	Q3W		39, 40
Cisplatin	60	≥ 3 hrs	d1	Q3W		
Capecitabine	625 PO BID		d1-21	Q3W		

藥品名	劑量 mg/m ²	輸注時間	給藥日	頻率	週期	參考文獻
Epirubicin	50	≥ 30 mins	d1	Q3W		38
Oxaliplatin	130	2 hrs	d1	Q3W		
Capecitabine	625 PO BID		d1-21	Q3W		

DCF modifications

藥品名	劑量 mg/m ²	輸注時間	給藥日	頻率	週期	參考文獻
Docetaxel	40	1 hr	d1	Q2W		36
Leucovorin	400	≥ 90 mins	d1	Q2W		
5-FU	400	5 mins	d1	Q2W		
5-FU	1000	22-24 hrs	d1-2	Q2W		
Cisplatin	40	≥ 2 hrs	d3	Q2W		

藥品名	劑量 mg/m ²	輸注時間	給藥日	頻率	週期	參考文獻
Docetaxel	50	1 hr	d1	Q2W		37
Oxaliplatin	85	2 hrs	d1	Q2W		
5-FU	1200	22-24 hrs	d1-2	Q2W		

參考文獻

1. Van Hagen P, Hulshof MC, van Lanschot, J.J, et al. Preoperative Chemoradiotherapy for Esophageal or Junctional Cancer. N Engl J Med 2012;366:2074-2084.
2. Conroy T, Galais MP, Raoul JL, et al. Definitive chemoradiotherapy with FOLFOX versus fluorouracil and cisplatin in patients with oesophageal cancer (PRODIGE5/ ACCORD17): final results of a randomised, phase 2/3 trial. Lancet Oncol 2014;15:305-314.
3. Khushalani NI, Leichman CG, Proulx G, et al. Oxaliplatin in combination with protracted-infusion fluorouracil and radiation: report of a clinical trial for patients with esophageal cancer. J Clin Oncol 2002;20:2844-2850.
4. Tepper J, Krasna MJ, Niedzwiecki D, et al. Phase III trial of trimodality therapy with cisplatin, fluorouracil, radiotherapy, and surgery compared with surgery alone for esophageal cancer: CALGB 9781. J Clin Oncol 2008;26:1086-1092.

5. Bedenne L, Michel P, Bouche O, et al. Chemoradiation followed by surgery compared with chemoradiation alone in squamous cancer of the esophagus: FFCD 9102. *J Clin Oncol* 2007; 25:1160-1168.
6. Sharma R, Yang GY, Nava HR, et al. A single institution experience with neoadjuvant chemoradiation (CRT) with irinotecan (I) and cisplatin (C) in locally advanced esophageal carcinoma (LAEC) [abstract]. *J Clin Oncol* 2009;27 (Suppl 15):Abstract e15619.
7. Ajani JA, Winter K, Okawara GS, et al. Phase II trial of preoperative chemoradiation in patients with localized gastric adenocarcinoma (RTOG 9904): quality of combined modality therapy and pathologic response. *J Clin Oncol* 2006;24:3953-3958.
8. Al-Batran SE, Hofheinz RD, Pauligk C, et al. Histopathological regression after neoadjuvant docetaxel, oxaliplatin, fluorouracil, and leucovorin versus epirubicin, cisplatin, and fluorouracil or capecitabine in patients with resectable gastric or gastro-oesophageal junction adenocarcinoma (FLOT4-AIO): results from the phase 2 part of a multicentre, open-label, randomised phase 2/3 trial. *Lancet Oncol* 2016;17:1697-1708.
9. Ychou M, Boige V, Pignon J-P, et al. Perioperative chemotherapy compared with surgery alone for resectable gastroesophageal adenocarcinoma: an FNCLCC and FFCD multicenter phase III trial. *J Clin Oncol* 2011;29:1715-1721.
10. Alderson D, Langley RE, Nankivell MG, et al. Neoadjuvant chemotherapy for resectable oesophageal and junctional adenocarcinoma: Results from the UK Medical Research Council randomised OEO5 trial (ISRCTN 01852072) [abstract]. *J Clin Oncol* 2015;33 (15_suppl):Abstract 4002.
11. Minsky BD, Pajak TF, Ginsberg RJ, et al. INT 0123 (Radiation Therapy Oncology Group 94-05) phase III trial of combined-modality therapy for esophageal cancer: highdose versus standard-dose radiation therapy. *J Clin Oncol* 2002;20:1167-1174.
12. Urba SG, Orringer MB, Iannettoni M, et al. Concurrent cisplatin, paclitaxel, and radiotherapy as preoperative treatment for patients with locoregional esophageal carcinoma. *Cancer* 2003;98:2177-2183.
13. Li QQ, Liu MZ, Hu YH, et al. Definitive concomitant chemoradiotherapy with docetaxel and cisplatin in squamous esophageal carcinoma. *Dis Esophagus* 2010;23:253-259.
14. Day FL, Leong T, Ngan S, et al. Phase I trial of docetaxel, cisplatin and concurrent radical radiotherapy in locally

- advanced oesophageal cancer. Br J Cancer 2011;104:265-271.
15. Smalley SR, Benedetti JK, Haller DG, et al. Updated analysis of SWOG-directed intergroup study 0116: a phase III trial of adjuvant radiochemotherapy versus observation after curative gastric cancer resection. J Clin Oncol 2012;30:2327-2333
 16. Noh SH, Park SR, Yang HK, et al. Adjuvant capecitabine plus oxaliplatin for gastric cancer after D2 gastrectomy (CLASSIC): 5-year follow-up of an open-label, randomized phase 3 trial. Lancet Oncol 2014; 15:1389-1396.
 17. Bang YJ, Van Cutsem E, Feyereislova A, et al. Trastuzumab in combination with chemotherapy versus chemotherapy alone for treatment of HER2-positive advanced gastric or gastro-oesophageal junction cancer (ToGA): a phase 3, open-label, randomised controlled trial. Lancet 2010;376:687-697.
 18. Lorenzen S, Schuster T, Porschen R, et al. Cetuximab plus cisplatin-5-fluorouracil versus cisplatin-5-fluorouracil alone in first-line metastatic squamous cell carcinoma of the esophagus: a randomized phase II study of the Arbeitsgemeinschaft Internistische Onkologie. Ann Oncol 2009;20:1667-1673.
 19. Al-Batran S-E, Hartmann JT, Probst S, et al. Phase III trial in metastatic gastroesophageal adenocarcinoma with fluorouracil, leucovorin plus either oxaliplatin or cisplatin: a study of the Arbeitsgemeinschaft Internistische Onkologie. J Clin Oncol 2008;26:1435-1442.
 20. Bouche O, Raoul JL, Bonnetain F, et al. Randomized multicenter phase II trial of a biweekly regimen of fluorouracil and leucovorin (LV5FU2), LV5FU2 plus cisplatin, or LV5FU2 plus irinotecan in patients with previously untreated metastatic gastric cancer: a Federation Francophone de Cancerologie Digestive Group Study--FFCD 9803. J Clin Oncol 2004;22:4319-4328.
 21. Kang YK, Kang WK, Shin DB, et al. Capecitabine/cisplatin versus 5-fluorouracil/cisplatin as first-line therapy in patients with advanced gastric cancer: a randomised phase III noninferiority trial. Ann Oncol 2009;20:666-673.
 22. Enzinger PC, Burtress B, Hollis D, et al. CALGB 80403/ECOG 1206: A randomized phase II study of three standard chemotherapy regimens (ECF, IC, FOLFOX) plus cetuximab in metastatic esophageal and GE junction cancer [abstract]. J Clin Oncol 2010;28 (Suppl 15):Abstract 4006.
 23. Kim GM, Jeung HC, Rha SY, et al. A randomized phase II trial of S-1-oxaliplatin versus capecitabine-oxaliplatin in advanced gastric cancer. Eur J Cancer 2012;48:518-526.

24. Ilson DH, Forastiere A, Arquette M, et al. A phase II trial of paclitaxel and cisplatin in patients with advanced carcinoma of the esophagus. *Cancer J* 2000;6:316-323.
25. Petrasch S, Welt A, Reinacher A, et al. Chemotherapy with cisplatin and paclitaxel in patients with locally advanced, recurrent or metastatic oesophageal cancer. *Br J Cancer* 1998;78:511-514.
26. Gadgeel SM, Shields AF, Heilbrun LK, et al. Phase II study of paclitaxel and carboplatin in patients with advanced gastric cancer. *Am J Clin Oncol* 2003;26:37-41.
27. Ajani JA, Fodor MB, Tjulandin SA, et al. Phase II multi-institutional randomized trial of docetaxel plus cisplatin with or without fluorouracil in patients with untreated, advanced gastric, or gastroesophageal adenocarcinoma. *J Clin Oncol* 2005;23:5660-5667.
28. Kim JY, Do YR, Park KU, et al. A multi-center phase II study of docetaxel plus cisplatin as first-line therapy in patients with metastatic squamous cell esophageal cancer. *Cancer Chemother Pharmacol* 2010;66:31-36.
29. Ohtsu A, Shimada Y, Shirao K, et al. Randomized phase III trial of fluorouracil alone versus fluorouracil plus cisplatin versus uracil and tegafur plus mitomycin in patients with unresectable, advanced gastric cancer: The Japan Clinical Oncology Group Study (JCOG9205). *J Clin Oncol* 2003;21:54-59.
30. Hong YS, Song SY, Lee SI, et al. A phase II trial of capecitabine in previously untreated patients with advanced and/or metastatic gastric cancer. *Ann Oncol* 2004;15:1344-1347.
31. Albertsson M, Johansson B, Friesland S, et al. Phase II studies on docetaxel alone every third week, or weekly in combination with gemcitabine in patients with primary locally advanced, metastatic, or recurrent esophageal cancer. *Med Oncol* 2007;24:407-412.
32. Ford HE, Marshall A, Bridgewater JA, et al. Docetaxel versus active symptom control for refractory oesophagogastric adenocarcinoma (COUGAR-02): an open-label, phase 3 randomised controlled trial. *Lancet Oncol* 2014;15:78-86.
33. Ajani JA, Ilson DH, Daugherty K, et al. Activity of taxol in patients with squamous cell carcinoma and adenocarcinoma of the esophagus. *J Natl Cancer Inst* 1994;86:1086-1091.
34. Ilson DH, Wadleigh RG, Leichman LP, Kelsen DP. Paclitaxel given by a weekly 1-h infusion in advanced esophageal cancer. *Ann Oncol* 2007;18:898-902.

35. Guimbaud R, Louvet C, Ries P, et al. Prospective, randomized, multicenter, phase III study of fluorouracil, leucovorin, and irinotecan versus epirubicin, cisplatin, and capecitabine in advanced gastric adenocarcinoma: A French Intergroup (Fédération Francophone de Cancérologie Digestive, Fédération Nationale des Centres de Lutte Contre le Cancer, and Groupe Coopérateur Multidisciplinaire en ncologie) Study. *J Clin Oncol* 2014;32:3520-3526.
36. Shah MA, Janjigian YY, Stoller R, et al. Randomized multicenter phase II study of modified docetaxel, cisplatin, and fluorouracil (DCF) versus DCF plus growth factor support in patients with metastatic gastric adenocarcinoma: a study of the US Gastric Cancer Consortium. *J Clin Oncol* 2015;33:3874-3879.
37. Shankaran V, Mulcahy MF, Hochster HS, et al. Docetaxel, oxaliplatin, and 5-fluorouracil for the treatment of metastatic or unresectable gastric or gastroesophageal junction (GEJ) adenocarcinomas: Preliminary results of a phase II study. *Gastrointestinal Cancers Symposium* 2009:Abstract 47.
38. Elkerm YM, Elsaid A, AL-Batran S, Pauligk C. Final results of a phase II trial of docetaxel-carboplatin-FU in locally advanced gastric carcinoma [abstract]. Presented at the *Gastrointestinal Cancers Symposium* 2008. Abstract 38.
39. Ross P, Nicolson M, Cunningham D, et al. Prospective randomized trial comparing mitomycin, cisplatin, and protracted venous-infusion fluorouracil (PVI 5-FU) with epirubicin, cisplatin, and PVI 5-FU in advanced esophagogastric cancer. *J Clin Oncol* 2002;20:1996-2004.
40. Sumpter K, Harper-Wynne C, Cunningham D, et al. Report of two protocol planned interim analyses in a randomised multicentre phase III study comparing capecitabine with fluorouracil and oxaliplatin with cisplatin in patients with advanced oesophagogastric cancer receiving ECF. *Br J Cancer* 2005;92:1976-1983.
41. Cunningham D, Starling N, Rao S, et al. Capecitabine and oxaliplatin for advanced esophagogastric cancer. *N Engl J Med* 2008;358:36-46.
42. Le DT, Durham JN, Smith KN, et al. Mismatch repair deficiency predicts response of solid tumors to PD-1 blockade. *Science* 2017;357:409-413.
43. Javle MM, Yang G, Nwogu CE, et al. Capecitabine, oxaliplatin and radiotherapy: a phase IB neoadjuvant study for esophageal cancer with gene expression analysis. *Cancer Invest* 2009;27:193-200.
44. Lee SS, Kim SB, Park SI, et al. Capecitabine and cisplatin chemotherapy (XP) alone or sequentially combined chemoradiotherapy containing XP regimen in patients with three different settings of stage IV esophageal cancer. *Jpn J*

- Clin Oncol 2007;37:829-835.
45. Macdonald JS, Smalley SR, Benedetti J, et al. Chemoradiotherapy after surgery compared with surgery alone for adenocarcinoma of the stomach or gastroesophageal junction. *N Engl J Med* 2001;345:725-730.
 46. Jansen EP, Boot H, Saunders MP, et al. A phase I-II study of postoperative capecitabine-based chemoradiotherapy in gastric cancer. *Int J Radiat Oncol Biol Phys* 2007;69:1424-1428.
 47. Leong T, Joon DL, Willis D, et al. Adjuvant chemoradiation for gastric cancer using epirubicin, cisplatin, and 5-fluorouracil before and after three-dimensional conformal radiotherapy with concurrent infusional 5-fluorouracil: a multicenter study of the trans-tasman radiation oncology group. *Int J Radiat Oncol Biol Phys* 2011;79:690-695.
 48. Lee HS, Choi Y, Hur WJ, et al. Pilot study of postoperative adjuvant chemoradiation for advanced gastric cancer: adjuvant 5-FU/cisplatin and chemoradiation with capecitabine. *World J Gastroenterol* 2006;12:603-607.
 49. Wolff K, Wein A, Reulbach U, et al. Weekly high-dose 5-fluorouracil as a 24-h infusion and sodium folinic acid (AIO regimen) plus irinotecan in patients with locally advanced nonresectable and metastatic adenocarcinoma or squamous cell carcinoma of the oesophagus: a phase II trial. *Anticancer Drugs* 2009;20:165-173.
 50. Kelly R, Ajani J, Kuzdzal J, et al. Adjuvant nivolumab in resected esophageal or gastroesophageal junction cancer following neoadjuvant chemoradiation therapy: first results of the CheckMate 577 study. [abstract]. Presented at the Oral Presentation presented at the ESMO 2020 Annual Meeting; September 19-21, 2020; Virtual Meeting.
 51. Moehler M, Shitara K, Garrido M, et al. Nivolumab plus chemotherapy versus chemotherapy as first-line treatment for advanced gastric cancer/gastroesophageal junction cancer/ esophageal adenocarcinoma: first results of the CheckMate 649 study. [abstract]. Presented at the Oral Presentation presented at the ESMO 2020 Annual Meeting; September 19-21, 2020; Virtual Meeting.
 52. Kato K., Sun JM., M. S, et al. Pembrolizumab plus chemotherapy versus chemotherapy as first-line therapy in patients with advanced esophageal cancer: the phase 3 KEYNOTE-590 study. [abstract]. Presented at the Presented at ESMO Annual Meeting; September 19-21, 2020; Virtual Meeting.
 53. Chung HC, et al First-line pembrolizumab/placebo plus trastuzumab and chemotherapy in HER2-positive advanced

- gastric cancer: KEYNOTE-811. *Future Oncol* 2021;17:491-501.
54. Doki Y, Ajani JA, Kato K, et al. Nivolumab Combination Therapy in Advanced Esophageal Squamous-Cell Carcinoma. *N Engl J Med*. 2022 Feb 3;386(5):449-462.
55. Kojima T, Shah MA, Muro K, et al. KEYNOTE-181 Investigators. Randomized Phase III KEYNOTE-181 Study of Pembrolizumab Versus Chemotherapy in Advanced Esophageal Cancer. *J Clin Oncol*. 2020 Dec 10;38(35):4138-4148. doi: 10.1200/JCO.20.01888. Epub 2020 Oct 7. PMID: 33026938.
56. Lala M, Li TR, de Alwis DP, et al. A six-weekly dosing schedule for pembrolizumab in patients with cancer based on evaluation using modelling and simulation. *Eur J Cancer*. 2020 May;131:68-75. doi: 10.1016/j.ejca.2020.02.016. Epub 2020 Apr 15. Erratum in: *Eur J Cancer*. 2021 Feb;144:400. PMID: 32305010.
57. Janjigian YY, Shitara K, Moehler M, et al. First-line nivolumab plus chemotherapy versus chemotherapy alone for advanced gastric, gastro-oesophageal junction, and oesophageal adenocarcinoma (CheckMate 649): a randomised, open-label, phase 3 trial. *Lancet*. 2021 Jul 3;398(10294):27-40. doi: 10.1016/S0140-6736(21)00797-2. Epub 2021 Jun 5. PMID: 34102137; PMCID: PMC8436782.
58. NCCN Guideline v4.2024. Esophageal and Esophagogastric Junction Cancers. ESOPH-F 11 of 22.
59. Shitara K, Lordick F, Bang YJ, et al. Zolbetuximab plus mFOLFOX6 in patients with CLDN18.2-positive, HER2-negative, untreated, locally advanced unresectable or metastatic gastric or gastro-oesophageal junction adenocarcinoma (SPOTLIGHT): a multicentre, randomised, double-blind, phase 3 trial. *Lancet*. 2023 May 20;401(10389):1655-1668. doi: 10.1016/S0140-6736(23)00620-7.
60. Shah MA, Shitara K, et al. Zolbetuximab plus CAPOX in CLDN18.2-positive gastric or gastroesophageal junction adenocarcinoma: the randomized, phase 3 GLOW trial. *Nat Med*. 2023 Aug;29(8):2133-2141. doi: 10.1038/s41591-023-02465-7. Epub 2023 Jul 31. PMID: 37524953; PMCID: PMC10427418.
61. Xu J, Kato K, Raymond E, et al. Tislelizumab plus chemotherapy versus placebo plus chemotherapy as first-line treatment for advanced or metastatic oesophageal squamous cell carcinoma (RATIONALE-306): a global, randomised, placebo-controlled, phase 3 study. *Lancet Oncol*. 2023 May;24(5):483-495. doi: 10.1016/S1470-2045(23)00108-0.